Clinical Trial

Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies how well acalabrutinib works in treating patients with chronic graft versus host disease. Acalabrutinib may be an effective treatment for graft-versus-host disease caused by a stem cell transplant.
Protocol Amendment History 38 amendments
This ClinicalTrials.gov record has been amended 38 times since 2019-12-12; most recent amendment 2025-11-04.
Status change: Recruiting → Active, Not Recruiting 2025-05-01
Status change: Not Yet Recruiting → Recruiting 2020-09-10
Trial Details
NCT Number NCT04198922
Lead Sponsor Fred Hutchinson Cancer Center
Collaborators: AstraZeneca
Conditions Recurrent Moderate-Severe Chronic Graft Versus Host Disease, Hematopoietic and Lymphoid Cell Neoplasm
Enrollment 51 participants
Start Date 2020-12-11
Primary Completion 2025-09-29 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-11-05